Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men

Skov, Jeppe, Dejgaard, Anders, Frøkiær, Jørgen, Holst, Jens Juul, Jonassen, Thomas, Rittig, Søren, Christiansen, Jens Sandahl·2013·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2012-3855

Cited by (228)

Items 201–228 of 228

  1. Papel da dipeptidil peptidase IV na fisiopatologia da insuficiência cardíaca
    Thiago A. Salles · 2016
  2. Efeito do peptídeo-1 semelhante ao glucagon endógeno sobre a atividade do NHE3 em túbulo proximal renal
    Livia Xavier Soares Farah · 2015
  3. Efeito do peptídeo-1 semelhante ao glucagon endógeno sobre a atividade do NHE3 em túbulo proximal renal
    São Paulo, C. Girardi · 2015
  4. Терапия, основанная на инкретинах: почечные эффекты
    Anton Ivanovich Korbut, Vadim Valer'evich Klimontov · 2016 · CyberLeninK (CyberLeninka)
  5. Efeito combinado da vildagliptina e do valsartan no tratamento da insuficiência cardíaca em ratos
    Daniel F. Arruda-Junior · 2019
  6. The effects of teneligliptin on DNA damages in multiple metabolic organs of HFD-induced diabetic obese mice
    박가희 · 2020
  7. Cardiorenal effects of newer antidiabetic agents
    Athanasia K. Papazafiropoulou, Elias Georgopoulos, Stavros Antonopoulos · 2020 · Journal of Atherosclerosis Prevention and Treatment
  8. Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction
    Yong Chen, Shiying Shao, Xiaoling Zhang, Qinqin Xu, Ruping Pan · 2022 · SSRN Electronic Journal
  9. Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
    Satoru Kuriyama, Kei Matsumoto · 2022 · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
  10. Improving kidney protection in patients with type 2 diabetes
    Annemarie B. van der Aart‐van der Beek · 2023
  11. SGLT2 and GLP - 1 Inhibitors: Enlightening their Role beyond their Glucose Lowering Properties
    Geetanjali Mehra · 2024 · International Journal of Science and Research (IJSR)
  12. Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
    Hong Sang Choi, Eun Hui Bae · 2025 · Korean Journal of Medicine
  13. Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study
    Jimmy Joseph · 2025 · Cureus
  14. Weight loss following gastric bypass increases aldosterone reactivity to orthostatic stress in patients with obesity
    Joachim Zahnd, Nima Vakilzadeh, Nora Schwotzer, Mariëlle Hendriks‐Balk, Styliani Mantziari, Julien Sauser, Marc P Maillard, Eric Grouzmann, Lucie Favre, Grégoire Wuerzner · 2025 · Blood Pressure
  15. Semaglutide: Multilevel organ protection in type 2 diabetes – from the heart and kidneys to peripheral vessels
    Maria G. Pavlova · 2025 · Meditsinskiy sovet = Medical Council
  16. Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes
    Jorge Gabriel Ruiz-Sánchez, Roberto Sierra-Poyatos, Bogdana Luiza Luca, Begoña Sánchez-Lechuga, Naiara Modroño Móstoles, Teresa Montoya Álvarez, Diego Meneses, Raquel Sánchez-Lopez, Carlos Casado Cases, Víctor Pérez de Arenaza Pozo et al. · 2025 · Medicina Clínica (English Edition)
  17. Lethality is local, but survival is systemic: Temporal and multi-organ responses to chlorine gas exposure in a murine model
    Jonathan Boyd, Mackenzie S. Newman, Heather Connery, Katharine Warner, Colby Riexinger, Maria Chaves, Jared Brown, A Bauer, Nabarun Chakraborty, Rasha Hammamieh et al. · 2026 · Current Research in Toxicology
  18. Potential effect of the short-acting GLP-1 agonist exenatide on copeptin in healthy adults
    Sarah Baumann, Svenja Leibnitz, Cihan Atila, Christina Romberg, Matthias Hepprich, Kwadwo Antwi, Emanuel Christ, M Christ Crain · 2026 · Obesity and Endocrinology
  19. Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
    J K Zhang, Guanbin Gao, Meng He, Taolei Sun · 2026 · European Journal of Pharmacology
  20. Acute GLP ‐1 infusion in male adults lowers circulating angiotensin II without changing angiotensinogen, ACE , ACE2 , or angiotensin‐(1–7) concentrations
    Ali Asmar, Muskaan Akram, Charlotte Mehlin Sørensen, Jesper Kingo Andresen, Boye L. Jensen · 2026 · Physiological Reports
  21. Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
    Zara Siu Wa Chui, Yaqian Xue, Xiaoping Wu, Aimin Xu · 2026 · Pharmacological Reviews
  22. A clinical and experimental investigation of liraglutide effects on the brain-kidney axis
    Michael Paul Greenwood, Mohammed I. Alotaibi, Soledad Bárez‐López, Nathan W. P. Cantley, Sharon Merritt, Danijela Tatović, David Murphy · 2026 · Science Advances
  23. Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis
    Luciano Falcão, Leonardo de Barros Oliveira, Pedro Lucas Machado Magalhães, Abhishek Goyal, Mariana Letícia de Bastos Maximiano, Kenzo Ogasawara Donato, Rafael Andrade Sampaio Silva, João Victor Pereira Gonzalez, Anderson Matheus Pereira da Silva, Anderson Silva Corin et al. · 2026 · Headache The Journal of Head and Face Pain
  24. Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions
    Doğaç Okşen, Muzaffer Aslan, Yunus Emre Yavuz, Çağdaş Kaynak, Ebru Serin · 2026 · Frontiers in Endocrinology
  25. Long-acting RNAi therapeutics in hypertension: limitations of single-target AGT silencing and rational multi-target synergistic strategies
    Yi Lan, Xiaoxia Ye, Qingwei Zeng, Wenlong Zhou · 2026 · Frontiers in Pharmacology
  26. GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
    Jan Boeckhaus, John Andrew Sayer, Holly R. Mabillard · 2026 · Clinical Science
  27. GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
    Zena Adel Alwaily, Obaid Ur Rahman, Aung Thet Swe, Aya Abouayana, Navdeep Singh Sodhi, Mei Jia Goh, Adeel Ahmed, Tharun Adithya Natesan, Shahzaib Shahzad, Om Harsh Merchant et al. · 2026 · Archives of Medical Science - Atherosclerotic Diseases
  28. Urinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related Factors
    Răzvan Alexandru Dănău, Mădălina Andreea Munteanu, Andrei Mitel, Gabriel Predoiu, Ileana Secareanu, Viorel Jinga · 2026 · Journal of Clinical Medicine